questionsmedicales.fr
Acides aminés, peptides et protéines
Protéines
Protéines du sang
Immunoprotéines
Protéines du système du complément
Enzymes activatrices du complément
Complement C3-C5 Convertases
Complement C3-C5 Convertases : Questions médicales fréquentes
Termes MeSH sélectionnés :
Fanconi Anemia Complementation Group A Protein
Diagnostic
5
Déficience du complément
Tests de laboratoire
Tests de complément
Hémolyse
Infections
Maladies auto-immunes
Sérum
Activité enzymatique
Symptômes
5
Éruptions cutanées
Douleurs articulaires
Troubles neurologiques
Inflammation cérébrale
Infections bactériennes
Maladies auto-immunes
Déficience du complément
Symptômes cliniques
Prévention
5
Prévention
Diagnostic précoce
Alimentation équilibrée
Nutrition
Suivi médical
Complications
Conseils génétiques
Transmission héréditaire
Traitements
5
Immunoglobulines
Antibiotiques
Médicaments anti-inflammatoires
Inhibiteurs du complément
Transfusions sanguines
Protéines du complément
Thérapie génique
Déficiences génétiques
Médecine personnalisée
Soins individualisés
Complications
5
Infections graves
Maladies auto-immunes
Complications réversibles
Gestion des complications
Qualité de vie
Douleurs chroniques
Complications neurologiques
Troubles cognitifs
Lésions tissulaires
Réactions inflammatoires
Facteurs de risque
5
Antécédents familiaux
Maladies auto-immunes
Infections fréquentes
Déficience du complément
Maladies génétiques
Prédisposition
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Complement C3-C5 Convertases : Questions médicales les plus fréquentes",
"headline": "Complement C3-C5 Convertases : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Complement C3-C5 Convertases : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-03-14",
"dateModified": "2025-03-09",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Complement C3-C5 Convertases"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Enzymes activatrices du complément",
"url": "https://questionsmedicales.fr/mesh/D003166",
"about": {
"@type": "MedicalCondition",
"name": "Enzymes activatrices du complément",
"code": {
"@type": "MedicalCode",
"code": "D003166",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.124.486.274.045"
}
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Alternative pathway C3-C5 Convertases",
"alternateName": "Complement C3-C5 Convertases, Alternative Pathway",
"url": "https://questionsmedicales.fr/mesh/D050578",
"about": {
"@type": "MedicalCondition",
"name": "Alternative pathway C3-C5 Convertases",
"code": {
"@type": "MedicalCode",
"code": "D050578",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.124.486.274.045.387.500"
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Alternative pathway complement C3 convertase",
"alternateName": "Complement C3 Convertase, Alternative Pathway",
"url": "https://questionsmedicales.fr/mesh/D051561",
"about": {
"@type": "MedicalCondition",
"name": "Alternative pathway complement C3 convertase",
"code": {
"@type": "MedicalCode",
"code": "D051561",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.124.486.274.045.387.500.374"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Alternative pathway C5 convertase",
"alternateName": "Complement C5 Convertase, Alternative Pathway",
"url": "https://questionsmedicales.fr/mesh/D051566",
"about": {
"@type": "MedicalCondition",
"name": "Alternative pathway C5 convertase",
"code": {
"@type": "MedicalCode",
"code": "D051566",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.124.486.274.045.387.500.750"
}
}
}
]
},
{
"@type": "MedicalWebPage",
"name": "Classical pathway C3-C5 Convertases",
"alternateName": "Complement C3-C5 Convertases, Classical Pathway",
"url": "https://questionsmedicales.fr/mesh/D050579",
"about": {
"@type": "MedicalCondition",
"name": "Classical pathway C3-C5 Convertases",
"code": {
"@type": "MedicalCode",
"code": "D050579",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.124.486.274.045.387.750"
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Classical pathway complement C3 convertase",
"alternateName": "Complement C3 Convertase, Classical Pathway",
"url": "https://questionsmedicales.fr/mesh/D051574",
"about": {
"@type": "MedicalCondition",
"name": "Classical pathway complement C3 convertase",
"code": {
"@type": "MedicalCode",
"code": "D051574",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.124.486.274.045.387.750.500"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Classical pathway C5 convertase",
"alternateName": "Complement C5 Convertase, Classical Pathway",
"url": "https://questionsmedicales.fr/mesh/D051577",
"about": {
"@type": "MedicalCondition",
"name": "Classical pathway C5 convertase",
"code": {
"@type": "MedicalCode",
"code": "D051577",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.124.486.274.045.387.750.750"
}
}
}
]
},
{
"@type": "MedicalWebPage",
"name": "Mannose-Binding Protein-Associated Serine Proteases",
"alternateName": "Mannose-Binding Protein-Associated Serine Proteases",
"url": "https://questionsmedicales.fr/mesh/D050606",
"about": {
"@type": "MedicalCondition",
"name": "Mannose-Binding Protein-Associated Serine Proteases",
"code": {
"@type": "MedicalCode",
"code": "D050606",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.124.486.274.045.387.875"
}
}
}
],
"about": {
"@type": "MedicalCondition",
"name": "Complement C3-C5 Convertases",
"alternateName": "Complement C3-C5 Convertases",
"code": {
"@type": "MedicalCode",
"code": "D050577",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "John D Lambris",
"url": "https://questionsmedicales.fr/author/John%20D%20Lambris",
"affiliation": {
"@type": "Organization",
"name": "Department of Laboratory Medicine and Pathology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA."
}
},
{
"@type": "Person",
"name": "Tom Eirik Mollnes",
"url": "https://questionsmedicales.fr/author/Tom%20Eirik%20Mollnes",
"affiliation": {
"@type": "Organization",
"name": "Research Laboratory, Nordland Hospital, 8092 Bodø, Norway."
}
},
{
"@type": "Person",
"name": "Dimitrios C Mastellos",
"url": "https://questionsmedicales.fr/author/Dimitrios%20C%20Mastellos",
"affiliation": {
"@type": "Organization",
"name": "National Center for Scientific Research 'Demokritos', Athens, Greece."
}
},
{
"@type": "Person",
"name": "Giuseppe Remuzzi",
"url": "https://questionsmedicales.fr/author/Giuseppe%20Remuzzi",
"affiliation": {
"@type": "Organization",
"name": "Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Bergamo, Italy."
}
},
{
"@type": "Person",
"name": "Markus Huber-Lang",
"url": "https://questionsmedicales.fr/author/Markus%20Huber-Lang",
"affiliation": {
"@type": "Organization",
"name": "Institute of Clinical and Experimental Trauma Immunology, University Hospital of Ulm, Ulm, Germany."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Pan-cancer analysis of the prognostic and immunological role of Fanconi anemia complementation group E.",
"datePublished": "2023-01-04",
"url": "https://questionsmedicales.fr/article/36685883",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.3389/fgene.2022.1024989"
}
},
{
"@type": "ScholarlyArticle",
"name": "Next-generation sequencing reveals novel variants and large deletion in FANCA gene in Polish family with Fanconi anemia.",
"datePublished": "2022-07-19",
"url": "https://questionsmedicales.fr/article/35854323",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1186/s13023-022-02424-4"
}
},
{
"@type": "ScholarlyArticle",
"name": "Pan-cancer analysis of the tumorigenic role of Fanconi anemia complementation group D2 (FANCD2) in human tumors.",
"datePublished": "2023-12-15",
"url": "https://questionsmedicales.fr/article/38104669",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.ygeno.2023.110762"
}
},
{
"@type": "ScholarlyArticle",
"name": "Fanconi anemia complementation group D2 promotes sensitivity of endometrial cancer cells to chemotherapeutic agents by inhibiting the ferroptosis pathway.",
"datePublished": "2024-01-13",
"url": "https://questionsmedicales.fr/article/38218826",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1186/s12905-023-02857-4"
}
},
{
"@type": "ScholarlyArticle",
"name": "Fanconi Anemia Neuroinflammatory Syndrome (FANS): Brain Lesions and Neurologic Injury in Fanconi Anemia.",
"datePublished": "2024-03-24",
"url": "https://questionsmedicales.fr/article/38522093",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1182/bloodadvances.2024012577"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Acides aminés, peptides et protéines",
"item": "https://questionsmedicales.fr/mesh/D000602"
},
{
"@type": "ListItem",
"position": 3,
"name": "Protéines",
"item": "https://questionsmedicales.fr/mesh/D011506"
},
{
"@type": "ListItem",
"position": 4,
"name": "Protéines du sang",
"item": "https://questionsmedicales.fr/mesh/D001798"
},
{
"@type": "ListItem",
"position": 5,
"name": "Immunoprotéines",
"item": "https://questionsmedicales.fr/mesh/D007162"
},
{
"@type": "ListItem",
"position": 6,
"name": "Protéines du système du complément",
"item": "https://questionsmedicales.fr/mesh/D003165"
},
{
"@type": "ListItem",
"position": 7,
"name": "Enzymes activatrices du complément",
"item": "https://questionsmedicales.fr/mesh/D003166"
},
{
"@type": "ListItem",
"position": 8,
"name": "Complement C3-C5 Convertases",
"item": "https://questionsmedicales.fr/mesh/D050577"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Complement C3-C5 Convertases - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Complement C3-C5 Convertases",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-02",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Complement C3-C5 Convertases",
"description": "Comment diagnostiquer une déficience en convertases C3-C5 ?\nQuels tests sont utilisés pour évaluer l'activité du complément ?\nQuels signes cliniques suggèrent une activation du complément ?\nPeut-on mesurer l'activité des convertases dans le sang ?\nQuels marqueurs biologiques sont associés aux convertases ?",
"url": "https://questionsmedicales.fr/mesh/D050577?mesh_terms=Fanconi+Anemia+Complementation+Group+A+Protein&page=1#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Complement C3-C5 Convertases",
"description": "Quels symptômes indiquent une activation excessive du complément ?\nComment se manifestent les troubles liés aux convertases ?\nLes troubles du complément causent-ils des symptômes neurologiques ?\nQuels signes indiquent une déficience en C3 ?\nLes symptômes varient-ils selon le type de déficience ?",
"url": "https://questionsmedicales.fr/mesh/D050577?mesh_terms=Fanconi+Anemia+Complementation+Group+A+Protein&page=1#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Complement C3-C5 Convertases",
"description": "Peut-on prévenir les déficiences en complément ?\nQuelles mesures préventives peuvent réduire les infections ?\nLes patients doivent-ils éviter certains aliments ?\nComment le suivi médical aide-t-il à prévenir les complications ?\nLes conseils génétiques sont-ils utiles pour les familles ?",
"url": "https://questionsmedicales.fr/mesh/D050577?mesh_terms=Fanconi+Anemia+Complementation+Group+A+Protein&page=1#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Complement C3-C5 Convertases",
"description": "Quels traitements sont disponibles pour les déficiences en complément ?\nComment traiter une activation excessive du complément ?\nLes transfusions sanguines aident-elles en cas de déficience ?\nY a-t-il des thérapies géniques pour les déficiences en complément ?\nLes traitements sont-ils personnalisés selon le patient ?",
"url": "https://questionsmedicales.fr/mesh/D050577?mesh_terms=Fanconi+Anemia+Complementation+Group+A+Protein&page=1#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Complement C3-C5 Convertases",
"description": "Quelles complications peuvent survenir avec une déficience en C3 ?\nLes complications sont-elles réversibles ?\nComment les complications affectent-elles la qualité de vie ?\nLes complications neurologiques sont-elles fréquentes ?\nQuelles sont les complications liées à l'activation excessive du complément ?",
"url": "https://questionsmedicales.fr/mesh/D050577?mesh_terms=Fanconi+Anemia+Complementation+Group+A+Protein&page=1#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Complement C3-C5 Convertases",
"description": "Quels facteurs augmentent le risque de déficience en complément ?\nL'âge influence-t-il le risque de troubles du complément ?\nLes infections fréquentes sont-elles un facteur de risque ?\nLe sexe joue-t-il un rôle dans les troubles du complément ?\nLes maladies génétiques augmentent-elles le risque ?",
"url": "https://questionsmedicales.fr/mesh/D050577?mesh_terms=Fanconi+Anemia+Complementation+Group+A+Protein&page=1#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostiquer une déficience en convertases C3-C5 ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des tests sanguins mesurant les niveaux de C3 et C5 peuvent indiquer une déficience."
}
},
{
"@type": "Question",
"name": "Quels tests sont utilisés pour évaluer l'activité du complément ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les tests d'hémolyse et les dosages de protéines du complément sont courants."
}
},
{
"@type": "Question",
"name": "Quels signes cliniques suggèrent une activation du complément ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des symptômes comme des infections récurrentes ou des maladies auto-immunes peuvent indiquer une activation."
}
},
{
"@type": "Question",
"name": "Peut-on mesurer l'activité des convertases dans le sang ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des tests spécifiques peuvent évaluer l'activité des convertases dans le sérum."
}
},
{
"@type": "Question",
"name": "Quels marqueurs biologiques sont associés aux convertases ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les niveaux de C3a et C5a, produits de clivage, sont des marqueurs importants."
}
},
{
"@type": "Question",
"name": "Quels symptômes indiquent une activation excessive du complément ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des symptômes comme des éruptions cutanées, des douleurs articulaires et de la fièvre peuvent survenir."
}
},
{
"@type": "Question",
"name": "Comment se manifestent les troubles liés aux convertases ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Ils peuvent se manifester par des infections fréquentes et des réactions inflammatoires."
}
},
{
"@type": "Question",
"name": "Les troubles du complément causent-ils des symptômes neurologiques ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des troubles neurologiques peuvent survenir en raison d'une inflammation cérébrale."
}
},
{
"@type": "Question",
"name": "Quels signes indiquent une déficience en C3 ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des infections bactériennes récurrentes et des maladies auto-immunes peuvent être des signes."
}
},
{
"@type": "Question",
"name": "Les symptômes varient-ils selon le type de déficience ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les symptômes peuvent varier selon que la déficience concerne C3 ou C5."
}
},
{
"@type": "Question",
"name": "Peut-on prévenir les déficiences en complément ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "La prévention est difficile, mais un diagnostic précoce peut aider à gérer les symptômes."
}
},
{
"@type": "Question",
"name": "Quelles mesures préventives peuvent réduire les infections ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des vaccinations et une bonne hygiène peuvent aider à réduire le risque d'infections."
}
},
{
"@type": "Question",
"name": "Les patients doivent-ils éviter certains aliments ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Il n'y a pas de restrictions alimentaires spécifiques, mais une alimentation équilibrée est conseillée."
}
},
{
"@type": "Question",
"name": "Comment le suivi médical aide-t-il à prévenir les complications ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Un suivi régulier permet d'identifier et de traiter rapidement les complications potentielles."
}
},
{
"@type": "Question",
"name": "Les conseils génétiques sont-ils utiles pour les familles ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les conseils génétiques peuvent aider à comprendre les risques de transmission."
}
},
{
"@type": "Question",
"name": "Quels traitements sont disponibles pour les déficiences en complément ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les traitements incluent des immunoglobulines intraveineuses et des antibiotiques prophylactiques."
}
},
{
"@type": "Question",
"name": "Comment traiter une activation excessive du complément ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des médicaments anti-inflammatoires et des inhibiteurs du complément peuvent être utilisés."
}
},
{
"@type": "Question",
"name": "Les transfusions sanguines aident-elles en cas de déficience ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les transfusions peuvent aider à restaurer les niveaux de protéines du complément."
}
},
{
"@type": "Question",
"name": "Y a-t-il des thérapies géniques pour les déficiences en complément ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des recherches sont en cours sur les thérapies géniques pour traiter ces déficiences."
}
},
{
"@type": "Question",
"name": "Les traitements sont-ils personnalisés selon le patient ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les traitements sont souvent adaptés en fonction des besoins individuels du patient."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent survenir avec une déficience en C3 ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des infections graves, des maladies auto-immunes et des complications rénales peuvent survenir."
}
},
{
"@type": "Question",
"name": "Les complications sont-elles réversibles ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines complications peuvent être gérées, mais d'autres peuvent être permanentes."
}
},
{
"@type": "Question",
"name": "Comment les complications affectent-elles la qualité de vie ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elles peuvent réduire la qualité de vie en entraînant des douleurs chroniques et des limitations fonctionnelles."
}
},
{
"@type": "Question",
"name": "Les complications neurologiques sont-elles fréquentes ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des complications neurologiques peuvent survenir, notamment des troubles cognitifs."
}
},
{
"@type": "Question",
"name": "Quelles sont les complications liées à l'activation excessive du complément ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des complications comme des lésions tissulaires et des réactions inflammatoires peuvent se produire."
}
},
{
"@type": "Question",
"name": "Quels facteurs augmentent le risque de déficience en complément ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des antécédents familiaux et certaines maladies auto-immunes augmentent le risque."
}
},
{
"@type": "Question",
"name": "L'âge influence-t-il le risque de troubles du complément ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le risque peut augmenter avec l'âge en raison de la dégradation du système immunitaire."
}
},
{
"@type": "Question",
"name": "Les infections fréquentes sont-elles un facteur de risque ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des infections fréquentes peuvent indiquer une déficience sous-jacente du complément."
}
},
{
"@type": "Question",
"name": "Le sexe joue-t-il un rôle dans les troubles du complément ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certaines déficiences sont plus fréquentes chez les femmes en raison de facteurs hormonaux."
}
},
{
"@type": "Question",
"name": "Les maladies génétiques augmentent-elles le risque ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certaines maladies génétiques peuvent prédisposer à des déficiences du complément."
}
}
]
}
]
}
Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale
Validation scientifique effectuée le 09/03/2025
Contenu vérifié selon les dernières recommandations médicales
7 publications dans cette catégorie
Affiliations :
Department of Laboratory Medicine and Pathology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
5 publications dans cette catégorie
Affiliations :
Research Laboratory, Nordland Hospital, 8092 Bodø, Norway.
K.G. Jebsen Thrombosis Research and Expertise Center, University of Tromsø, 9037 Tromsø, Norway.
Department of Immunology, Oslo University Hospital, University of Oslo, 0318 Oslo, Norway.
Centre of Molecular Inflammation Research, Norwegian University of Science and Technology, 7491 Trondheim, Norway; and.
Publications dans "Complement C3-C5 Convertases" :
5 publications dans cette catégorie
Affiliations :
National Center for Scientific Research 'Demokritos', Athens, Greece.
Publications dans "Complement C3-C5 Convertases" :
5 publications dans cette catégorie
Affiliations :
Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Bergamo, Italy.
L. Sacco Department of Biomedical and Clinical Sciences, University of Milan, Milan, Italy.
Publications dans "Complement C3-C5 Convertases" :
4 publications dans cette catégorie
Affiliations :
Institute of Clinical and Experimental Trauma Immunology, University Hospital of Ulm, Ulm, Germany.
Publications dans "Complement C3-C5 Convertases" :
4 publications dans cette catégorie
Affiliations :
Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Bergamo, Italy.
Publications dans "Complement C3-C5 Convertases" :
3 publications dans cette catégorie
Affiliations :
Department of Immunology, Genetics and Pathology, University Uppsala, Uppsala, Sweden.
Publications dans "Complement C3-C5 Convertases" :
3 publications dans cette catégorie
Publications dans "Complement C3-C5 Convertases" :
3 publications dans cette catégorie
Affiliations :
Centre de Recherche des Cordeliers, INSERM, Sorbonne Université, Université de Paris, Paris, France.
Publications dans "Complement C3-C5 Convertases" :
2 publications dans cette catégorie
Affiliations :
Linneaus Center for Bomaterials Chemistry, Linnaeus University, Kalmar, Sweden.
Publications dans "Complement C3-C5 Convertases" :
2 publications dans cette catégorie
Affiliations :
Deparment of Infection Biology, Leibniz Institute for Natural Product Research and Infection Biology, Jena, Germany.
Faculty of Life Sciences, Friedrich Schiller University Jena, Jena, Germany.
Publications dans "Complement C3-C5 Convertases" :
2 publications dans cette catégorie
Affiliations :
Department of Molecular Biology and Genetics, Aarhus University, DK-8000 Aarhus, Denmark.
Publications dans "Complement C3-C5 Convertases" :
2 publications dans cette catégorie
Affiliations :
Department of Molecular Biology and Genetics, Aarhus University, DK-8000 Aarhus, Denmark.
Publications dans "Complement C3-C5 Convertases" :
2 publications dans cette catégorie
Affiliations :
Research Laboratory, Nordland Hospital, 8092 Bodø, Norway.
Publications dans "Complement C3-C5 Convertases" :
2 publications dans cette catégorie
Affiliations :
Department of Molecular Biology and Genetics, Aarhus University, DK-8000 Aarhus, Denmark.
Publications dans "Complement C3-C5 Convertases" :
2 publications dans cette catégorie
Affiliations :
Department of Molecular Biology and Genetics, Aarhus University, DK-8000 Aarhus, Denmark.
Publications dans "Complement C3-C5 Convertases" :
2 publications dans cette catégorie
Affiliations :
Department of Molecular Biology and Genetics, Aarhus University, DK-8000 Aarhus, Denmark.
Publications dans "Complement C3-C5 Convertases" :
2 publications dans cette catégorie
Affiliations :
Department of Molecular Biology and Genetics, Aarhus University, DK-8000 Aarhus, Denmark.
Publications dans "Complement C3-C5 Convertases" :
2 publications dans cette catégorie
Affiliations :
Department of Biomedicine, Aarhus University, DK-8000 Aarhus, Denmark.
Publications dans "Complement C3-C5 Convertases" :
2 publications dans cette catégorie
Affiliations :
Department of Molecular Biology and Genetics, Aarhus University, DK-8000 Aarhus, Denmark; gra@mbg.au.dk.
Publications dans "Complement C3-C5 Convertases" :
Fanconi anemia (FA) genes contribute to tumorigenesis by regulating DNA repair. Despite its importance for assembly and functionality of the FA core complex, no pan-cancer analysis of...
Fanconi anemia (FA) is the most common inherited bone marrow failure syndrome. However, establishing its molecular diagnosis remains challenging. Chromosomal breakage analysis is the gold standard dia...
We report here on a family with FA diagnosis in two siblings. Mitomycin C (MMC) test revealed high level of chromosome breaks and radial figures. In both children, array-Comparative Genomic Hybridizat...
Although genetic testing in FA patients often requires a multi-method approach including chromosome breakage test, aCGH, and NGS, every effort should be made to make it available for whole FA families...
Monoubiquitination of FANCD2 is a central step in the activation of the Fanconi anemia (FA) pathway after DNA damage. Defects in the FA pathway centered around FANCD2 not only lead to genomic instabil...
Resistance can develop during treatment of advanced endometrial cancer (EC), leading to unsatisfactory results. Fanconi anemia complementation group D2 (Fancd2) has been shown to be closely related to...
Real-time quantitative PCR (RT-qPCR) was used to detect the expression of Fancd2 in EC tissues and cells. EC cells (Ishikawa) and paclitaxel-resistant EC cells (Ishikawa/TAX) were transfected to knock...
Compared with the normal tissues and endometrial epithelial cells, Fancd2 expression was significantly increased in EC tissues and Ishikawa cells, respectively. After knock-down of Fancd2, Ishikawa ce...
Fancd2 increases drug resistance in EC cells by inhibiting the cellular ferroptosis pathway....
Fanconi anemia (FA) is a complex inherited bone marrow failure syndrome characterized by chromosomal instability and defective DNA repair causing sensitivity to DNA interstrand cross-linking agents. O...
Liver hepatocellular carcinoma (LIHC) is a serious liver disease worldwide, and its pathogenesis is complicated....
This study investigated the potential role of FANCA in the advancement and prognosis of LIHC....
Public databases, quantitative reverse transcription polymerase chain reaction (qRT-PCR), western blot (WB) and immunohistochemistry (IHC) were employed to measure FANCA expression between tumor and n...
Expression analysis presented that FANCA had high expression level in LIHC tissues and cells. Receiver operating characteristic (ROC) curve analysis showed that FANCA was of great diagnosis value in L...
Our data revealed that high level of FANCA was closely associated with LIHC malignant progression, suggesting its potential utility as a diagnostic, predictive indicator, and therapeutic target....
Fanconi anemia (FA) is an autosomal or X-linked human disease, characterized by bone marrow failure, cancer susceptibility and various developmental abnormalities. So far, at least 22 FA genes (FANCA-...
Fanconi anemia is a rare genetic disorder affecting various body systems. Congenital abnormalities, poor hematopoiesis, a higher incidence of acute myeloid leukemia, myelodysplastic syndrome, and mali...
Fanconi anaemia (FA) is a rare autosomal recessive condition resulting in changes in the FANC gene family. This report describes a case of Fanconi anaemia in a family with complex biallelic variants. ...
FA patients are hypersensitive to preconditioning of bone marrow transplantation....
Assessment of the power of mitomycin C (MMC) test to assign FA patients....
We analysed 195 patients with hematological disorders using spontaneous and two types of chromosomal breakage tests (MMC and bleomycin). In case of presumed Ataxia telangiectasia (AT), patients' blood...
Seven patients were diagnosed as having FA. The number of spontaneous chromosomal aberrations was significantly higher in FA patients than in aplastic anemia (AA) patients including chromatid breaks, ...
MMC and Bleomycin tests together proved to be more informative than MMC test alone for the diagnostic classification of AA patients, while in vitro irradiation tests could help detect radiosensitive-a...